Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yuthavong, Yongyuth, Tarnchompoo, Bongkoch, Vilaivan, Tirayut, Chitnumsub, Penchit, Kamchonwongpaisan, Sumalee, Charman, Susan A., McLennan, Danielle N., White, Karen L., Vivas, Livia, Bongard, Emily, Thongphanchang, Chawanee, Taweechai, Supannee, Vanichtanankul, Jarunee, Rattanajak, Roonglawan, Arwon, Uthai, Fantauzzi, Pascal, Yuvaniyama, Jirundon, Charman, William N., Matthews, David
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2012
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3479511/
https://ncbi.nlm.nih.gov/pubmed/23035243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204556109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados